Biotech Values

[dav1234]

Medivation (MDVN +0.75%) and not Dendreon (DNDN -3.5%) is the more attractive acquisition target, says Jefferies analyst Biren Amin. This is because of the bright prospects for MDV3100, the prostate-cancer drug that Medivation half owns and the poor outlook for provenge, Dendreon's rival treatment